Skip to content
Search

Latest Stories

‘Outrage’: NPA slams government over 2025/26 GP contract as pharmacies await current year’s terms

NPA slams 2025-26 GP contract
Photo: iStock

The National Pharmacy Association (NPA) has come down heavily on the government, terming the GP contract offer a year ahead of pharmacies ‘an outrage’.

The government has on Thursday unveiled the first details of the next GP contract for 2025-26, including an extra £889 million ‘on top of the existing budget’ for general practice.


“It is an outrage that GP's have been offered their contract for the next financial year before pharmacies have even received an offer for the current year – nine months late,” Paul Rees, NPA chief executive, commented.

“There is huge strength of feeling among our members about their current financial position and this does nothing to reduce the chance of pharmacies being forced to take collective action to protect their services for patients.”

Last month, 99 per cent of NPA members voted in favour of limiting services to patients for the first time in its history if current levels of government underfunding is not reversed.

In the historic ballot, 97.8 per cent voted to serve notice on opening hours above the minimum required by their contract, with pharmacies being shut on weekends or weekday evenings whilst 93.3 per cent voted to withdraw making free home deliveries of medicines.

“The seemingly endless delays to this year’s contract negotiations only reinforces the belief that there is a lack of respect for pharmacies within government and leaves hardworking pharmacies abandoned in the dark, causing them stress and uncertainty about their future,” Rees said.

“Uncertainty about funding is preventing pharmacies from investing in better services and reform – instead making them take on debts or question whether they can continue at all.”

Rees asked the government to “get around the table” as soon as is possible to end the “crippling uncertainty and offer reassurance and security” to pharmacies.

Responding to the announcement, Community Pharmacy England chief executive Janet Morrison said: “It is extraordinary that the government has announced what looks to be a generous investment in general practice for 2025/26 before settling the contract for community pharmacies – many of whom are on the brink of collapse – for this financial year.

“For desperate pharmacy owners working hard to support their patients despite intolerable financial and operational pressures, today’s announcement will feel like more evidence of the inequity at the heart of primary care, and it is a further kick while they are down.”

She said the ongoing delays to Community Pharmacy Contractual Framework (CPCF) negotiations are “infuriating,” adding that: “It is clearly in everyone’s interests to have a strong general practice service, but without a stable network of community pharmacies to support them, any efforts to ease pressure on GPs will be wasted.”

While welcoming the assurances this week from ministers that the CPCF negotiations will commence early in the New Year, she said this will not be enough.

“Government and the NHS cannot be in any doubt that community pharmacies are chronically and dangerously underfunded and need urgent help. “Every further delay is likely too late for some pharmacy business and the communities and patients they serve. Community pharmacies simply cannot wait any longer for the good news they so desperately need,” she said.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less